We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Technology Treats Axillary Hyperhidrosis

By HospiMedica International staff writers
Posted on 22 Feb 2011
A new noninvasive, quick, outpatient procedure provides a lasting solution for primary axillary hyperhidrosis, commonly known as excessive underarm sweat.

The miraDry procedure entails delivering electromagnetic energy to the area beneath the underarm skin, where the sweat glands reside. More...
The treatment is noninvasive, and requires two hour-long doctor's office visits. The procedure is performed in three simple steps; placing temporary markings on the skin, administering local anesthesia, and treatment. Total patient appointment time is 60 minutes, with treatment itself taking approximately 40 minutes. A touch-up visit may be needed to treat any areas that may have been missed. Custom software guides the operators throughout the process, and patients begin to notice the effect of the treatment immediately following the procedure.

The miraDry System consists of a console, a handpiece, and a disposable tip, referred to as the miraDry bioTip, a single-use shield that helps ensure safety and efficacy for the patient as well as protection of the equipment. The system preferentially targets the region where sweat glands reside through physical rotation of dipole molecules; a proprietary cooling feature protects the superficial dermis. The result is thermal necrosis of the sweat glands and the protection of surrounding structures. The miraDry system is a product of Miramar Labs (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

"We are very excited to introduce a procedure for physicians that will help alleviate the suffering of millions of people, allowing them to lead better quality lives,” said Darrell Zoromski, President and CEO of Miramar Labs. "Axillary hyperhidrosis is a disease of silent sufferers, and we are thrilled to be able to offer a clinically proven, noninvasive, lasting solution to these patients.”

"While temporary, noninvasive solutions and surgery have been available, miraDry provides my patients with the opportunity for a truly lasting solution in a noninvasive office procedure,” said William Coleman III, MD, a clinical professor of dermatology and adjunct professor of surgery at Tulane University Health Sciences Center (New Orleans, LA, USA).

Hyperhidrosis is a condition characterized by abnormally increased perspiration, in excess of that required for regulation of body temperature. The cause of primary hyperhidrosis is unknown, although some claim that it is caused by sympathetic overactivity. Nervousness or excitement can exacerbate the situation for many sufferers, but other factors can play a role; certain foods and drinks, nicotine, caffeine, and smells can trigger a response.

Related Links:

Miramar Labs



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.